Key terms

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest PODD news

Today 4:58am ET SPY ETF Update, 3/29/2024 Mar 25 2:49am ET SPY ETF Update, 3/25/2024 Mar 22 7:20am ET Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO) Mar 21 7:40am ET Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS) Mar 21 5:55am ET SPY ETF Update, 3/21/2024 Mar 20 7:23am ET Insulet Appoints Ana Maria Chadwick as New CFO Mar 20 6:02am ET Insulet appoints Ana Maria Chadwick as CFO Mar 16 12:15pm ET Insulet’s Growth Trajectory Affirmed with a Buy Rating and Revised Target Price Mar 16 12:15pm ET Insulet price target lowered to $250 from $260 at Citi Mar 08 6:02am ET Insulet reports ‘positive’ results from Omnipod 5 trial Mar 07 6:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP) Mar 05 12:15am ET SPY ETF Update, 3/5/2024 Mar 01 4:12pm ET Insulet Enhances Equity Agreements and Compliance for 2024 Mar 01 10:50am ET Insulet participates in a conference call with JPMorgan Mar 01 4:55am ET Insulet participates in a conference call with JPMorgan Feb 29 5:13pm ET Insulet participates in a conference call with JPMorgan Feb 26 5:51am ET Insulet price target lowered to $213 from $214 at Barclays Feb 25 11:40pm ET Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD) Feb 25 11:36pm ET Insulet’s Strong Growth and Market Position Justify Buy Rating Despite Short-Term Revenue Guidance Concerns Feb 25 8:15pm ET Barclays Sticks to Its Hold Rating for Insulet (PODD) Feb 23 7:51am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD) Feb 23 7:40am ET Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY) Feb 23 7:20am ET Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Insulet (PODD) and Teleflex (TFX) Feb 23 7:20am ET Piper Sandler Remains a Buy on Insulet (PODD) Feb 23 7:11am ET Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT) Feb 23 5:55am ET Insulet’s Strong Performance and Promising Outlook Merit a Buy Rating Feb 23 12:20am ET Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Teleflex (TFX) and Madrigal Pharmaceuticals (MDGL) Feb 22 4:09pm ET Insulet sees FY24 revenue growth 12%-17%, consensus $1.98B Feb 22 4:09pm ET Insulet sees Q1 revenue growth 17%-20%, consensus $442.48M Feb 22 4:08pm ET Insulet reports Q4 adjusted EPS $1.40, consensus 66c Feb 07 6:10am ET Insulet gets CE Mark approval of Omnipod 5 integration with FreeStyle Libre 2

No recent news articles are available for PODD

No recent press releases are available for PODD

PODD Financials

1-year income & revenue

Key terms

PODD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

PODD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms